Article Sidebar
Published:
Apr 27, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Myocardin immunohistochemistry index is associated with clinical prognosis in nasopharyngeal carcinoma: a clinical practice-based cohort study
Abstract
Purpose: Recent findings have implicated the role of myocardin re-expression in carcinogenesisHowever, the clinical functions of myocardin in nasopharyngeal carcinoma (NPC) is not known yet. The purpose for the cohort research was to investigate whether myocardin re-expression level may predict clinical prognosis in NPC patients.
Methods: 148 NPC patients were recruited from September, 2005 to September, 2011 with median follow-up time of 4.5 years in a clinical practice setting. At study entry myocardin re-expression of these patients was determined using immunohistochemistry (IHC) and additional 20 normal nasopharyngeal tissues were included as control. Two-sample t-test was used to compare mean myocardin reexpression levels and Chi-square test was used for comparing tumour recurrence rate. Logistic regression analysis was used for tumour local control rate, and log-rank test, Kaplan-Meier estimates and Cox proportional hazard model for disease-free survival and overall survival.
Results: Myocardin IHC index was significantly downregulated in NPC samples than in normal
nasopharyngeal tissues (mean ± standard deviation, 61.2 ±31.5 vs. 109.9 ±73.6, P= 0.009). However, among NPC patients was observed a roughly V-shaped change of myocardin IHC index according to Tumour T-stage (P=0.067); meanwhile higher IHC level was associated with more tumour recurrence rate in NPC patients (High vs. Low: 21.6% vs. 8.1%; P=0.021). Logistic regression analysis equally showed high myocardin IHC level was an independent risk factor for local tumour control rate regardless of adjustments [High vs. Low: unadjusted Odds Ratio (OR) 0.320, 95% confidence interval (CI): 0.117 to 0.871; P=0.026]. Moreover, higher myocardin IHC level was associated with a marginal but not significant risk increase of disease-free survival [High vs. Low: adjusted Hazard Ratio (HR) 1.760, 95% CI: 0.981 to 3.158; log-rank: P=0.129]. A less obvious trend was observed with regard to overall survival [adjusted HR 1.409, 95% CI: 0.715 to 2.77; log-rank: P=0.745].
Conclusion: The study results suggested that high myocardin IHC index level could be a potential clinically prognostic intermediate biomarker for tumour recurrence for NPC patients in routine practice. Large well-designed cohort studies involving IHC re-expression change over time is needed.
